3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Purpura, Thrombotic Thrombocytopenic
1
Purpura, Thrombocytopenic, Idiopathic
1
Neoplasms, Plasma Cell
1
Lymphoma
1
Leukemia
1
COVID-19
1
Interventions
Cyclophosphamide
71
fludarabine phosphate
63
Busulfan
47
Peripheral Blood Stem Cell Transplantation
44
Tacrolimus
41
Mycophenolic Acid
37
Antilymphocyte Serum
37
Filgrastim
32
Cyclosporine
30
Melphalan
29
Whole-Body Irradiation
28
Radiotherapy
28
fludarabine
26
Methotrexate
23
Methylprednisolone
18
Etoposide
18
Cord Blood Stem Cell Transplantation
17
Rituximab
13
Alemtuzumab
13
Stem Cell Transplantation
12
Granulocyte Colony-Stimulating Factor
10
Sirolimus
9
Thiotepa
8
Cytarabine
8
sargramostim
7
Prednisone
7
Epoetin Alfa
7
Flow Cytometry
6
thymoglobulin
5
Trimethoprim, Sulfamethoxazole Drug Combination
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia
×
crexavibart
×
Plasma cell
×
Clear all
NCT05393999
2023-04-24
SABRE
Imperial College Healthcare NHS Trust
Phase 2
Withdrawn